Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.96 USD
+0.04 (1.37%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.89 -0.07 (-2.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Lisata Therapeutics, Inc.'s return on equity, or ROE, is -61.37% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that LSTA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
LSTA 2.96 +0.04(1.37%)
Will LSTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSTA
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
Other News for LSTA
Lisata Therapeutics Q2 2025 Earnings Preview
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business ...
12 Health Care Stocks Moving In Monday's Pre-Market Session
LSTA Shows Promising Results in Latest iLSTA Trial | LSTA Stock News
Lisata Therapeutics (LSTA) Completes Enrollment for Pancreatic Cancer Trial | LSTA Stock News